Better health-related quality of life in patients treated with sacubitril/valsartan compared with enalapril, irrespective of NYHA class: Analysis of EQ-5D in PARADIGM-HF
28 August 2017 (08:30 - 12:30)
Organised by:
Abstract
About the speaker
Novartis Pharmaceuticals UK Limited, Frimley (United Kingdom of Great Britain & Northern Ireland)
28 More presentations in this session
Access the full session
The Event
ESC Congress 2017
28 August 2017
08:30 CET
